CA3189460A1 - Egfr inhibitor - Google Patents
Egfr inhibitorInfo
- Publication number
- CA3189460A1 CA3189460A1 CA3189460A CA3189460A CA3189460A1 CA 3189460 A1 CA3189460 A1 CA 3189460A1 CA 3189460 A CA3189460 A CA 3189460A CA 3189460 A CA3189460 A CA 3189460A CA 3189460 A1 CA3189460 A1 CA 3189460A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- alkyl group
- substituent
- egfr
- group optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020-121525 | 2020-07-15 | ||
| JP2020121525 | 2020-07-15 | ||
| PCT/JP2021/026461 WO2022014639A1 (ja) | 2020-07-15 | 2021-07-14 | Ｅｇｆｒ阻害剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3189460A1 true CA3189460A1 (en) | 2022-01-20 |
Family
ID=79554696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3189460A Pending CA3189460A1 (en) | 2020-07-15 | 2021-07-14 | Egfr inhibitor |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230285397A1 (https=) |
| EP (1) | EP4197538A4 (https=) |
| JP (1) | JP7495983B2 (https=) |
| KR (1) | KR102873219B1 (https=) |
| CN (1) | CN116368136B (https=) |
| AU (1) | AU2021309779B2 (https=) |
| BR (1) | BR112023000770A2 (https=) |
| CA (1) | CA3189460A1 (https=) |
| MX (1) | MX2023000693A (https=) |
| PH (1) | PH12023550119A1 (https=) |
| TW (1) | TW202216152A (https=) |
| WO (1) | WO2022014639A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4183395A4 (en) * | 2020-07-15 | 2024-07-24 | Taiho Pharmaceutical Co., Ltd. | PYRIMIDINE COMPOUND-CONTAINING COMBINATION FOR USE IN TUMOR TREATMENT |
| BR112023000765A2 (pt) * | 2020-07-15 | 2023-02-07 | Taiho Pharmaceutical Co Ltd | Cristal de composto de pirimidina |
| EP4351737A4 (en) * | 2021-05-24 | 2025-05-14 | Taiho Pharmaceutical Co., Ltd. | Treatment methods for subjects with cancer having an aberration in egfr and/or her2 |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8426428B2 (en) * | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
| US9034885B2 (en) * | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
| TW201336847A (zh) | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| BR112018004175B8 (pt) | 2015-09-01 | 2023-10-31 | Taiho Pharmaceutical Co Ltd | Composto pirazolo[3,4-d]pirimidina, composição farmacêutica e usos terapêuticos do dito composto |
| ES2775751T3 (es) * | 2016-02-23 | 2020-07-28 | Taiho Pharmaceutical Co Ltd | Nuevo compuesto de pirimidina condensada o sal del mismo |
| PL3909584T3 (pl) * | 2019-01-11 | 2024-03-25 | Taiho Pharmaceutical Co., Ltd. | Związek pirymidynowy lub jego sól |
-
2021
- 2021-07-14 MX MX2023000693A patent/MX2023000693A/es unknown
- 2021-07-14 AU AU2021309779A patent/AU2021309779B2/en active Active
- 2021-07-14 CN CN202180061165.8A patent/CN116368136B/zh active Active
- 2021-07-14 CA CA3189460A patent/CA3189460A1/en active Pending
- 2021-07-14 EP EP21842292.1A patent/EP4197538A4/en not_active Withdrawn
- 2021-07-14 WO PCT/JP2021/026461 patent/WO2022014639A1/ja not_active Ceased
- 2021-07-14 TW TW110125853A patent/TW202216152A/zh unknown
- 2021-07-14 BR BR112023000770A patent/BR112023000770A2/pt unknown
- 2021-07-14 US US18/016,103 patent/US20230285397A1/en active Pending
- 2021-07-14 KR KR1020237001973A patent/KR102873219B1/ko active Active
- 2021-07-14 JP JP2022536419A patent/JP7495983B2/ja active Active
- 2021-07-14 PH PH1/2023/550119A patent/PH12023550119A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2022014639A1 (https=) | 2022-01-20 |
| BR112023000770A2 (pt) | 2023-02-07 |
| EP4197538A1 (en) | 2023-06-21 |
| AU2021309779A1 (en) | 2023-02-23 |
| JP7495983B2 (ja) | 2024-06-05 |
| WO2022014639A1 (ja) | 2022-01-20 |
| US20230285397A1 (en) | 2023-09-14 |
| MX2023000693A (es) | 2023-02-13 |
| KR20230026451A (ko) | 2023-02-24 |
| AU2021309779B2 (en) | 2024-06-27 |
| KR102873219B1 (ko) | 2025-10-17 |
| CN116368136A (zh) | 2023-06-30 |
| EP4197538A4 (en) | 2024-08-07 |
| TW202216152A (zh) | 2022-05-01 |
| PH12023550119A1 (en) | 2024-06-24 |
| CN116368136B (zh) | 2025-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7495983B2 (ja) | Ｅｇｆｒ阻害剤 | |
| CA3121722C (en) | Pyrimidine compound or salt thereof | |
| RU2581834C1 (ru) | Новое пиперидиновое соединение или его соль | |
| KR20100132023A (ko) | 아실티오우레아 화합물 또는 그 염 및 그 용도 | |
| KR101905295B1 (ko) | 나프티리딘디온 유도체 | |
| JP7373664B2 (ja) | 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ | |
| RU2817044C1 (ru) | Ингибитор egfr | |
| RU2787992C1 (ru) | Пиримидиновое соединение или его соль | |
| BR122024008319A2 (pt) | Composto pirimidina, composição farmacêutica e agente antitumoral que compreendem o mesmo e usos do dito composto para o tratamento de tumor | |
| BR112021013460B1 (pt) | Composto pirimidina, composição farmacêutica e agente antitumoral que compreendem o mesmo e usos do dito composto para o tratamento de tumor | |
| WO2022014638A1 (ja) | ピリミジン化合物の結晶 | |
| HK40090490B (zh) | Egfr抑制剂 | |
| HK40090490A (zh) | Egfr抑制剂 | |
| HK40056369B (zh) | 嘧啶化合物或其盐 | |
| HK40056369A (en) | Pyrimidine compound or salt thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230112 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240819 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241028 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250415 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250415 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250627 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250627 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250903 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250903 |